Abbott Laboratories is a global healthcare company that operates in various segments, providing a wide range of products and services. The company focuses on branded generic pharmaceuticals, diagnostic systems and tests, nutritional products, and medical devices, catering to both international and domestic markets . Abbott's diversified portfolio includes significant contributions from emerging markets and innovations in medical devices, allowing it to maintain a balanced revenue stream across its segments .
- Medical Devices - Offers products in rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care, with the FreeStyle Libre system being a major growth driver .
- Established Pharmaceutical Products - Focuses on branded generic pharmaceuticals primarily sold in emerging markets, significantly contributing to international sales .
- Diagnostic Products - Includes a broad line of diagnostic systems and tests, with notable sales from COVID-19 testing, although this has decreased as the pandemic shifted to an endemic state .
- Nutritional Products - Encompasses both pediatric and adult nutrition, with products like Ensure and Glucerna leading growth, particularly in the U.S. market .
You might also like
What went well
- Abbott's Diabetes Care segment achieved strong growth, with 21% overall increase in FreeStyle Libre sales and 26% growth in the U.S., positioning the product to exceed $6 billion in revenue this year and ahead of the goal of $10 billion by 2028 . The successful U.S. launch of Lingo, targeting non-diabetic individuals, is showing very strong early interest and higher than expected reorder rates, indicating additional growth opportunities .
- Structural Heart sales grew 25% globally and 40% in the U.S., driven by strong performance in Left Atrial Appendage (LAA) closure and tricuspid devices . Positive clinical data, such as 95% closure rates for Amulet sustained after 45 days, and the development of Amulet 2.0, along with investments in clinical trials and potential expanded coverage, support continued growth .
- Abbott expects continued high single-digit revenue growth and 10% EPS growth into 2025, supported by a strong pipeline with recently launched products contributing around $1 billion in revenue this year, expected to double next year . The company is focusing on gross margin expansion and disciplined investment allocation, positioning it for operating margin improvement .
What went wrong
- Abbott is facing significant legal liabilities related to NEC infant formula lawsuits, which may impact its financial position and could potentially lead to product withdrawal from the U.S. market if unresolved .
- The judge in the current trial has not allowed key evidence (the joint statement from FDA, CDC, and NIH) to be entered into evidence, potentially increasing the risk of unfavorable legal outcomes for Abbott .
- Abbott intends to resolve these lawsuits faster than the typical decade-long litigation process, which may result in financial strain and increased liabilities .
Q&A Summary
-
2025 Guidance
Q: Are high single-digit revenue and 10% EPS growth reasonable for 2025?
A: Robert Ford acknowledged that analyst estimates of high single-digit revenue growth and 10% EPS growth for 2025 are a reasonable starting point. Without the "COVID cloud" affecting comparisons, the company is well-positioned to achieve these targets, driven by its $40 billion revenue base and strong pipeline. -
Libre Growth and CGM Market
Q: How is Libre performing, and what's the outlook for the CGM market?
A: Libre grew 21% globally and 26% in the U.S. in Q3. Abbott views the CGM market as a mass market opportunity, aiming for Libre to be a $6 billion-plus product growing 20% this year. The company is ahead of its target 15% CAGR to reach $10 billion in sales by 2028. The launch of Lingo, targeting non-diabetics, has shown strong early interest, with higher reorder rates than in the UK. -
Confidence in Full-Year Guidance
Q: How confident are you in maintaining full-year guidance despite underperformance in Nutrition and Diagnostics?
A: Despite underperformance in Nutrition and Diagnostics, Abbott remains confident in its full-year revenue guidance of 9.5% to 10% growth. Issues in Nutrition were due to temporary challenges in international pediatric markets, which are being addressed. Core Lab Diagnostics was impacted by the VBP implementation in China, but excluding China, international Core Lab was up double digits. The diversified portfolio allows overperformance in other areas to compensate. -
Investment Spending and Share Buyback
Q: How are you managing investment spending and the share repurchase program?
A: Abbott reduced expenses from 37% in 2019 to about 34% this year, achieving $1 billion in spending leverage over five years. Investments focus on high-growth areas like EP, structural heart, and diagnostics. The Board approved a new $7 billion buyback program, with $750 million repurchased in Q3. The buybacks aim to correct a perceived disconnect in the PE ratio, not to drive EPS through share count reduction.
-
Given the competitive data expected in the tricuspid space and potential mortality benefits shown by competitors, how does Abbott plan to sustain growth in its structural heart franchises, particularly in the left atrial appendage closure and tricuspid markets?
-
With concerns about U.S. provider capacity potentially limiting growth in structural heart markets like TAVR, what strategies does Abbott have in place to mitigate potential bottlenecks and ensure continued adoption of its therapies?
-
Considering the strong statement from the FDA, CDC, and NIH regarding the lack of conclusive evidence linking infant formula to NEC, how does Abbott plan to address the ongoing lawsuits, and what measures are being taken to ring-fence liabilities related to these cases?
-
As recently launched products are expected to contribute about $1 billion in revenue this year, double that of 2023, what specific plans does Abbott have to sustain this momentum in innovation and revenue growth into 2025 and beyond?
-
With the expansion of the FreeStyle Libre system and the launch of Lingo for non-insulin-intensive type 2 diabetes patients, how does Abbott plan to navigate potential pricing pressures and maintain gross margins, especially as the market expands to a broader, price-sensitive population?
Q3 2024 Earnings Call
- Issued Period: Q3 2024
- Guided Period: Q4 2024 and FY 2024
- Guidance:
- Adjusted Earnings Per Share (EPS) for Q4 2024: $1.31 to $1.37 .
- Impact of Foreign Exchange on Q4 2024 Sales: Unfavorable impact of less than 1% .
Q2 2024 Earnings Call
- Issued Period: Q2 2024
- Guided Period: FY 2024
- Guidance:
- Full Year Organic Sales Growth (excluding COVID testing sales): 9.5% to 10% .
- Full Year Adjusted EPS: $4.61 to $4.71 .
- Foreign Exchange Impact on Full Year Sales: Unfavorable impact of more than 2.5% .
- Foreign Exchange Impact on Q3 2024 Sales: Unfavorable impact of approximately 3% .
- Third Quarter Adjusted EPS: $1.18 to $1.22 .
Q1 2024 Earnings Call
- Issued Period: Q1 2024
- Guided Period: FY 2024
- Guidance:
- Full Year Adjusted EPS: $4.55 to $4.70 .
- Organic Sales Growth (excluding COVID testing-related sales): 8.5% to 10% .
- Foreign Exchange Impact on Full Year Sales: Unfavorable impact of approximately 2.5% .
- Foreign Exchange Impact on Q2 2024 Sales: Unfavorable impact of approximately 3% .
- Second Quarter Adjusted EPS: $1.08 to $1.12 .
Q4 2023 Earnings Call
- Issued Period: Q4 2023
- Guided Period: FY 2024 and Q1 2024
- Guidance:
- Full Year Adjusted EPS: $4.50 to $4.70 .
- First Quarter 2024 Adjusted EPS: $0.93 to $0.97 .
- Total Underlying Base Business Organic Sales Growth (Excluding COVID Testing Sales): 8% to 10% for the full year .
- Foreign Exchange Impact on Full Year Sales: Unfavorable impact of a little more than 1% .
- Foreign Exchange Impact on Q1 2024 Sales: Unfavorable impact of approximately 2% .
- Nonoperating Income: Approximately $130 million .
- Adjusted Tax Rate: 15% .